CRISPR biosensing with lateral flow assays for point of care Diagnostics: Overcoming commercial development challenges

IF 11.8 1区化学 Q1 CHEMISTRY, ANALYTICAL

Trends in Analytical Chemistry Pub Date : 2025-04-21 DOI:10.1016/j.trac.2025.118275

Tim Hall , Sneha Gulati , Rui Sang , Zhengyang Jia , Flyn Mckinnirey , Graham Vesey , Ewa Goldys , Fei Deng

{"title":"CRISPR biosensing with lateral flow assays for point of care Diagnostics: Overcoming commercial development challenges","authors":"Tim Hall , Sneha Gulati , Rui Sang , Zhengyang Jia , Flyn Mckinnirey , Graham Vesey , Ewa Goldys , Fei Deng","doi":"10.1016/j.trac.2025.118275","DOIUrl":null,"url":null,"abstract":"<div><div>The combination of lateral flow assays (LFAs) with CRISPR biosensing technologies offers a new frontier in point-of-care (POC) diagnostics. LFAs are widely used for their simplicity, rapid results, and ease of use, enabling detection of various targets including proteins and nucleic acids. However, traditional LFAs often struggle with sensitivity, especially in detecting viral nucleic acids like SARS-CoV-2. CRISPR biosensing systems, particularly those using Cas12 and Cas13 effectors, enhance LFA performance by providing highly sensitive and specific detection of nucleic acids. These effectors, upon recognizing a target sequence, trigger collateral cleavage activity, amplifying the detection signal. This approach has been used in diagnostic tools such as DETECTR (Cas12a) and SHERLOCK (Cas13a), which have shown PCR-level sensitivity and specificity for detecting viral RNA, including SARS-CoV-2, with faster and more cost-effective results. By integrating CRISPR technologies into LFAs, these hybrid systems are poised to offer powerful solutions for sensitive, low-cost, and user-friendly diagnostics, especially in resource-limited settings. This review summarizes the recent advancements in CRISPR-based LFAs, exploring their mechanisms, advantages, and limitations. In addition, this review also outlines the commercial development challenges and discussed the future prospects.</div></div>","PeriodicalId":439,"journal":{"name":"Trends in Analytical Chemistry","volume":"189 ","pages":"Article 118275"},"PeriodicalIF":11.8000,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in Analytical Chemistry","FirstCategoryId":"1","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0165993625001438","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, ANALYTICAL","Score":null,"Total":0}

引用次数: 0

Abstract

The combination of lateral flow assays (LFAs) with CRISPR biosensing technologies offers a new frontier in point-of-care (POC) diagnostics. LFAs are widely used for their simplicity, rapid results, and ease of use, enabling detection of various targets including proteins and nucleic acids. However, traditional LFAs often struggle with sensitivity, especially in detecting viral nucleic acids like SARS-CoV-2. CRISPR biosensing systems, particularly those using Cas12 and Cas13 effectors, enhance LFA performance by providing highly sensitive and specific detection of nucleic acids. These effectors, upon recognizing a target sequence, trigger collateral cleavage activity, amplifying the detection signal. This approach has been used in diagnostic tools such as DETECTR (Cas12a) and SHERLOCK (Cas13a), which have shown PCR-level sensitivity and specificity for detecting viral RNA, including SARS-CoV-2, with faster and more cost-effective results. By integrating CRISPR technologies into LFAs, these hybrid systems are poised to offer powerful solutions for sensitive, low-cost, and user-friendly diagnostics, especially in resource-limited settings. This review summarizes the recent advancements in CRISPR-based LFAs, exploring their mechanisms, advantages, and limitations. In addition, this review also outlines the commercial development challenges and discussed the future prospects.

查看原文本刊更多论文

CRISPR生物传感与护理点诊断的横向流动分析：克服商业发展挑战

横向流动检测法（LFA）与 CRISPR 生物传感技术的结合为护理点诊断（POC）开辟了新的领域。LFA 因其操作简单、结果快速、易于使用而被广泛使用，可检测包括蛋白质和核酸在内的各种靶标。然而，传统的 LFA 通常在灵敏度方面存在问题，尤其是在检测 SARS-CoV-2 等病毒核酸方面。CRISPR 生物传感系统，特别是使用 Cas12 和 Cas13 效应器的系统，通过提供高灵敏度和特异性的核酸检测，提高了 LFA 的性能。这些效应器在识别目标序列时会触发附带的裂解活动，从而放大检测信号。这种方法已被用于 DETECTR（Cas12a）和 SHERLOCK（Cas13a）等诊断工具中，它们在检测包括 SARS-CoV-2 在内的病毒 RNA 方面显示出 PCR 水平的灵敏度和特异性，而且检测结果更快、更具成本效益。通过将 CRISPR 技术整合到 LFA 中，这些混合系统有望为灵敏、低成本和用户友好型诊断提供强大的解决方案，尤其是在资源有限的环境中。本综述总结了基于 CRISPR 的 LFA 的最新进展，探讨了它们的机制、优势和局限性。此外，本综述还概述了商业开发所面临的挑战，并讨论了未来前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Trends in Analytical Chemistry 化学-分析化学

CiteScore

20.00

自引率

4.60%

发文量

257

审稿时长

3.4 months

期刊介绍： TrAC publishes succinct and critical overviews of recent advancements in analytical chemistry, designed to assist analytical chemists and other users of analytical techniques. These reviews offer excellent, up-to-date, and timely coverage of various topics within analytical chemistry. Encompassing areas such as analytical instrumentation, biomedical analysis, biomolecular analysis, biosensors, chemical analysis, chemometrics, clinical chemistry, drug discovery, environmental analysis and monitoring, food analysis, forensic science, laboratory automation, materials science, metabolomics, pesticide-residue analysis, pharmaceutical analysis, proteomics, surface science, and water analysis and monitoring, these critical reviews provide comprehensive insights for practitioners in the field.